Clinical value of monitoring plasma octreotide levels during chronic octreotide long-acting repeatable therapy in carcinoid patients

Pancreas

Volumn 37, Issue 1, 2008, Pages 94-100

  Woltering, Eugene A ^a,g   Salvo, Vergilio A ^a   O'Dorisio, Thomas M ^b   Lyons, John ^a   Li, Gang ^c   Zhou, Ying ^c   Seward, Jacky R ^a   Go, Vay Liang W ^d   Vinik, Arthur I ^e   Mamikunian, Paris ^f   Mamikunian, Gregg ^f  

^a LOUISIANA STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF IOWA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e EASTERN VIRGINIA MEDICAL SCHOOL   (United States)

^f Inter Science Institute   (United States)

^g NONE   (United States)

Author keywords

Carcinoid syndrome, tachyphylaxis; Plasma drug levels; Somatostatin analogs; Somatostatin receptors; Sustained release preparations; Symptoms

Indexed keywords

OCTREOTIDE; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS;

ARTICLE; CANCER PATIENT; CARCINOID; DRUG BLOOD LEVEL; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; PATIENT MONITORING; PRIORITY JOURNAL; RETREATMENT; STATISTICAL MODEL; STATISTICAL SIGNIFICANCE; BLOOD; CLINICAL TRIAL; DELAYED RELEASE FORMULATION; DRUG MONITORING; INTRAMUSCULAR DRUG ADMINISTRATION; METABOLISM; MULTICENTER STUDY; NEUROENDOCRINE TUMOR; PROSPECTIVE STUDY; RETROSPECTIVE STUDY; TIME; TREATMENT OUTCOME; UNITED STATES;

ANTINEOPLASTIC AGENTS, HORMONAL; CARCINOID TUMOR; DELAYED-ACTION PREPARATIONS; DRUG MONITORING; HUMANS; INJECTIONS, INTRAMUSCULAR; NEUROENDOCRINE TUMORS; OCTREOTIDE; PROSPECTIVE STUDIES; RETROSPECTIVE STUDIES; TIME FACTORS; TREATMENT OUTCOME; UNITED STATES;

EID: 49649124111     PISSN: 08853177     EISSN: None     Source Type: Journal    
DOI: 10.1097/MPA.0b013e31816907ab     Document Type: Article

References (8)

1. Woltering EA, Mamikunian PM, Zietz S, et al. Effect of octreotide LAR dose and weight on octreotide blood levels in patients with neuroendocrine tumors. Pancreas. 2005;31:392-400.
2. Harris AG, O'Dorisio TM, Woltering EA, et al. Consensus statement: octreotide dose titration in secretory diarrhea. Management Consensus Development Panel. Dig Dis Sci. 1995;40:1464-1473.
3. Rubin J, Ajani J, Schirmer W, et al. Octreotide acetate long-acting formulation versus open-label subcutaneous octreotide acetate in malignant carcinoid syndrome. J Clin Oncol. 1999;17:600-606.
4. Weckbecker G, Liu R, Tolcsvai L, et al. Antiproliferative effects of the somatostatin analogue octreotide (SMS 201-995) on ZR-75-1 human breast cancer cells in vivo and in vitro. Cancer Res. 1992;52:4973-4978.
5. O'Dorisio MS, Chen F, O'Dorisio TM, et al. Characterization of somatostatin receptors on human neuroblastoma tumors. Cell Growth Differ. 1994;5:1-8.
6. Bertherat J, Chanson P, Dewailly D, et al. Somatostatin receptors, adenylate cyclase activity, and growth hormone (GH) response to octreotide in GH-secreting adenomas. J Clin Endocrinol Metabol. 1993;77:1577-1583.
7. Anthony LB, Stafford S, Cronin M, et al. Octreotide LAR doses used in clinical practice: results from an internet survey and a clinical practice. Proc Am Soc Clin Oncol. 2004;23:4274.
8. Littell R, Milliken G, Stroup W, et al. SAS System for Mixed Models. Cary, NC: SAS Press; 1996.